Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Cash from Investing Activities: 2020-2024

Historic Cash from Investing Activities for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to -$12.0 million.

  • SAB Biotherapeutics' Cash from Investing Activities fell 11167.05% to -$129.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$110.7 million, marking a year-over-year decrease of 418.09%. This contributed to the annual value of -$12.0 million for FY2024, which is 7733.63% down from last year.
  • Per SAB Biotherapeutics' latest filing, its Cash from Investing Activities stood at -$12.0 million for FY2024, which was down 7,733.63% from -$152,704 recorded in FY2023.
  • SAB Biotherapeutics' 5-year Cash from Investing Activities high stood at -$152,704 for FY2023, and its period low was -$12.7 million during FY2020.
  • Moreover, its 3-year median value for Cash from Investing Activities was -$2.1 million (2022), whereas its average is -$4.7 million.
  • Per our database at Business Quant, SAB Biotherapeutics' Cash from Investing Activities soared by 92.69% in 2023 and then slumped by 7,733.63% in 2024.
  • Over the past 5 years, SAB Biotherapeutics' Cash from Investing Activities (Yearly) stood at -$12.7 million in 2020, then increased by 13.98% to -$10.9 million in 2021, then soared by 80.90% to -$2.1 million in 2022, then surged by 92.69% to -$152,704 in 2023, then crashed by 7,733.63% to -$12.0 million in 2024.